Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

Modern Pathology

Volumn 23, Issue 6, 2010, Pages 824-833

  Scarpa, Aldo ^a,b   Mantovani, William ^a   Capelli, Paola ^a   Beghelli, Stefania ^a,b   Boninsegna, Letizia ^a   Bettini, Rossella ^a   Panzuto, Francesco ^c   Pederzoli, Paolo ^a   Fave, Gianfranco Delle ^c   Falconi, Massimo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b ARC NET Center for Applied Research on Cancer   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Endocrine; Grading; Pancreas; Prognosis; Staging; TNM; Tumors

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INFILTRATION; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; DISTANT METASTASIS; FOLLOW UP; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

ADULT; AGED; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WORLD HEALTH ORGANIZATION;

EID: 77953148115     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.58     Document Type: Article

References (23)

1. Heitz PU, Komminoth P, Perren A, et al. Pancreatic endocrine tumours. In: DeLellis RA, Lloyd RV, Heitz PU, et al. (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs. IARC Press: Lyon, 2004, pp 177-182.
2. Hruban RH, Bishop Pitman M, Klimstra DSL. Endocrine Neoplasms. In: Silverberg SG, Sobin LH (eds). Tumors of the Pancreas. ARP AFIP: Washington, 2007, pp 251-304.
3. Klöppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of gastroenteropancreatic neuro-endocrine tumors. Virchows Arch 2007;451(Suppl 1).
4. Capelli P, Martignoni G, Pedica F, et al. Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med 2009;133:350-364.
5. Hurban RH, Bishop Pitman M, Klimstra DSL. Endocrine Neoplasms. In: Silverberg SG, Sobin LH (eds). Tumors of the Pancreas. ARP, AFIP: Washington, 2007, pp 259-262.
6. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781.
7. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreo-tide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13: 1213-1221.
8. de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulino-ma. Neuroendocrinology 2006;84:183-188.
9. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006;84:196-211.
10. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84:173-182.
11. O'Toole D, Salazar R, Falconi M, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006;84:189-195.
12. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-560.
13. Schindl M, Kaczirek K, Kaserer K, et al. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg 2000;24:1312-1318.
14. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007;31:1677-1682.
15. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
16. Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-7803.
17. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95:627-635.
18. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009;40:30-40.
19. Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256-265.
20. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
21. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-1019
22. American Joint Committee on Cancer. Exocrine and endocrine pancreas. In: Edge S, Byrd D, Compton C, et al (eds). AJCC Cancer Staging Manual (ed Seventh). Berlin, Springer, 2010, pp 241-249.
23. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007;205:558-563.